Select Language
Free Registration

HLA-A*1101 & B2M & EBV LMP2 (SSCSSCPLSK)

HLA-A*1101 & B2M & EBV LMP2 (SSCSSCPLSK) Product List

  • Product Category

    Protein (2)

  • Product Status

    Launched (2)

  • Species

    Human (2)

  • Tag

    His Tag (1)His Tag & Avi Tag (1)

  • Conjugate

    PE Labeled (1)Biotin-labeled (1)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeature
HL2-H82Eq
Human
HEK293
Biotinylated Human HLA-A*11:01&B2M&EBV LMP2 (SSCSSCPLSK) Complex Protein (Monomer, MALS verified)
HL2-HP2H5
Human
HEK293
PE-Labeled Human HLA-A*11:01&B2M&EBV LMP2 (SSCSSCPLSK) Tetramer Protein
Total: 2
  • 1

HLA-A*1101 & B2M & EBV LMP2 (SSCSSCPLSK) Background

Epstein-Bar Virus (EBV), also known as human herpesvirus 4, belongs to gamma herpes virus family and is a very common human virus worldwide. EBV causes infectious mononucleosis (IM) and also associates to some specific types of cancers such as Burkitt’s lymphoma (BL) and gastric carcinoma (GC). Glycoprotein B (gB) plays an important role in viral entry by binding with αvβ6/αvβ8 integrins to trigger the membrane fusion and entry process of epithelial cells, which makes it become an great target for EBV research. Epstein-Bar Virus (EBV), also known as human herpesvirus 4, belongs to gamma herpes virus family and is a very common human virus worldwide. EBV causes infectious mononucleosis (IM) and also associates to some specific types of cancers such as Burkitt’s lymphoma (BL) and gastric carcinoma (GC). Glycoprotein B (gB) plays an important role in viral entry by binding with αvβ6/αvβ8 integrins to trigger the membrane fusion and entry process of epithelial cells, which makes it become an great target for EBV research. The Human HLA-A*1101 EBV LMP2 (SSCSSCPLSK)complex protein is a complex of HLA-A*1101 of the MHC Class I, B2M and SSCSSCPLSK peptide of the EBV LMP2.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
ZG-2001ZG2001; ZG-2001Phase 2 ClinicalSuzhou Zelgen Biopharmaceuticals Co LtdSolid tumours; Neoplasms
Details
ELI-002Amph-CpG-7909; ELI-002; ELI-002 2P; VED-002Phase 2 ClinicalElicio TherapeuticsOvarian Neoplasms; Solid tumours; Neoplasm, Residual; Cholangiocarcinoma; Colorectal Neoplasms; Bile Duct Neoplasms; Gallbladder Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung
Details
Pooled mutant-KRAS peptide vaccine (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins)Phase 1 ClinicalSidney Kimmel Comprehensive Cancer CenterPancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
mRNA-5671mRNA-5671Phase 1 ClinicalModerna Inc, Merck & Co IncPancreatic Neoplasms; Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
mDC3/8-KRAS Vaccine (University of Pennsylvania)Phase 1 ClinicalUniversity Of PennsylvaniaCarcinoma, Pancreatic Ductal
Details
PF-07985045PF-07985045; PF-5045Phase 1 ClinicalPfizer IncColorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung
Details
BGB-53038BGB-53038Phase 1 ClinicalSolid tumours; Esophageal Neoplasms; Stomach Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Esophageal adenocarcinoma; Carcinoma, Pancreatic Ductal; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
PF-07934040PF-4040; PF-07934040Phase 1 ClinicalPfizer IncColorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung
Details
ASP-4396ASP4396; ASP-4396Phase 1 ClinicalAstellas Pharma IncSolid tumours
Details
QTX-3544QTX-3544; QTX3544Phase 1 ClinicalQuanta Therapeutics IncSolid tumours; Neoplasms
Details
BI-3706674BI-3706674; BI3706674; BI 3706674Phase 1 ClinicalC.H. Boehringer Sohn Ag & Co. KgSolid tumours; Stomach Neoplasms; Esophageal Neoplasms
Details
YL-17231YL-17231; YL17231; TEB-17231Phase 1 ClinicalYL-PharmaSolid tumours; Neoplasms
Details
QTX-3034QTX3034; QTX-3034Phase 1 ClinicalQuanta Therapeutics IncSolid tumours; Neoplasms
Details
SY-5933SY-5933; SY5933Phase 1 ClinicalSolid tumours; Neoplasms
Details
RNA tumor vaccine (First Affiliated Hospital Bengbu Medical College)Phase 1 ClinicalFirst Affiliated Hospital Bengbu Medical CollegeSolid tumours
Details
RMC-9805RM-036; RMC-9805Phase 1 ClinicalRevolution Medicines IncSolid tumours; Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung
Details
LUNA-18LUNA-18Phase 1 ClinicalChugai Pharmaceutical Co LtdSolid tumours
Details
BEBT-607C200825009-FP; BEBT-607Phase 1 ClinicalGuangzhou BeBetter Medicine Technology CoSolid tumours; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
BI-1701963BI-1701963Phase 1 ClinicalSolid tumours; Colorectal Neoplasms
Details
CWG-59rCWG-59r; CWG-59-r; CWG59rClinicalCellworks GroupNeoplasms
Details
CWG-71bCWG-71b; CWG-71-b; CWG71bClinicalCellworks GroupNeoplasms
Details
CWG-89CWG-89ClinicalCellworks GroupNeoplasms
Details
CWG-71a (Cellworks Group)CWG-71aClinicalCellworks Group IncNeoplasms
Details
  • Product List
  • Clinical Drug Information
Share to:

Join UsLegalSite MapPrivacy PolicyTerms and Conditions
Website Feedback
Contact Us

+49 800 0826645

order.de@acrobiosystems.com
tech.de@acrobiosystems.com

BettinastraBe 30, 60325 Frankfurt am Main